Pancreatic cancer action network - Join us
Clinical Trial
Finder
Retrieving Trials
Retrieving Trials...

Back to Trial Search

Phase Ib Study of the Safety of TAS-102 in Combination With Temozolomide for Metastatic Pancreatic Neuroendocrine Tumors

Summary

The purpose of this phase I study is to establish the maximum tolerated doses or recommended phase 2 dose (RP2D) of temozolomide (TMZ) and TAS-102 when these agents are used in combination and to evaluate the safety profile of this drug combination among patients with pancreatic neuroendocrine tumors.

General Information

NCT#: NCT02943733
Study ID: UW16034
Trial Phase: Phase I

Trial Sponsor: University of Wisconsin
Therapies Used in This Trial: Temozolomide, Trifluridine/Tipiricil

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account?

Request an Account


  • In order to view this information, you need to be signed in as a Health Care Provider.
  • You need to be signed in as a Health Care Provider. Please request an account.
  • In order to view this information, you need to be signed in as a Health Care Provider.
  • In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
  • This information is restricted to validated Health Care Providers.

Eligibility



-------------------------------------------------------------------------------------------

  • In order to view this information, you need to be signed in as a Health Care Provider.
  • You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
  • ------------------------------------------------------------------------------------------------------
  • In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information


Back to Trial Search